Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gingilacer is an oral care product line developed for the prevention and management of gum problems, particularly gingival bleeding and gingivitis. It is available primarily as a toothpaste and mouthwash. The formulation contains active ingredients such as zinc chloride (astringent to reduce gum bleeding), triclosan (antibacterial agent), potassium glycyrrhizate (anti-inflammatory), cymenol (antimicrobial), sodium monofluorophosphate or fluoride ion (for enamel strengthening and anti-caries action). The mechanism of action involves inhibition of bacterial activity to reduce dental plaque formation—the main cause of gingivitis—while the astringent effect of zinc helps restore gum tissue integrity and reduce inflammation. The product is alcohol-free, suitable for daily use, does not irritate gums or stain teeth, and is indicated for people with delicate gums or those prone to periodontal disease[1][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gingilacer.